Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hematopoietic stem cells

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    246 result(s) found for: Hematopoietic stem cells. Displaying page 1 of 13.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-002383-13 Sponsor Protocol Number: Cord_Blood_Expansion_(SR-1) Start Date*: 2016-10-18
    Sponsor Name:Erasmus MC
    Full Title: Umbilical cord blood transplantation in high-risk hematological patients using stemregenin-1 expanded hematopoietic stem cells. A feasibility study focussing on engraftment and hematopoietic recov...
    Medical condition: Patients with high-risk hematological diseases, who need a allogeneic stem cell transplantation but who lack a matched unrelated donor
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061187 Haematopoietic neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001188-55 Sponsor Protocol Number: HOVON115 Start Date*: 2012-07-10
    Sponsor Name:HOVON Foundation
    Full Title: Double umbilical cord blood transplantation in high-risk hematological patients. A phase II study focussing on the mechanism of graft predominance
    Medical condition: Patients with high-risk hematological diseases, who need a allogeneic stem cell transplantation but who lack a matched unrelated donor
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061187 Haematopoietic neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011817-26 Sponsor Protocol Number: BHS-UCB2009 Start Date*: 2010-10-21
    Sponsor Name:UZ Brussel VUB
    Full Title: A pilot study to assess the feasibility of unrelated umbilical cord blood transplantation with coinfusion of third-party mesenchymal stem cells after myeloablative or nonmyeloablative conditioning ...
    Medical condition: Adult patients with hematological malignancies
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013798-16 Sponsor Protocol Number: Start Date*: 2010-02-01
    Sponsor Name:Royal Liverpool and Broadgreen University Hospitals NHS Trust
    Full Title: A comparison of plerixafor/G-CSF with chemotherapy/G-CSF for stem cell transplantation
    Medical condition: Patients with lymphoma or myeloma, who require high dose chemotherapy with autologous stem cell rescue (known colloquially as an autograft). Plerixafor is used to mobilise the autologous stem cells...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10053946 Stem cell mobilization LLT
    14.0 10042613 - Surgical and medical procedures 10019028 Blood and blood product treatment HLT
    14.0 10042613 - Surgical and medical procedures 10042613 Surgical and medical procedures SOC
    14.0 10042613 - Surgical and medical procedures 10025309 Haematological and lymphoid tissue therapeutic procedures HLGT
    14.0 10042613 - Surgical and medical procedures 10053943 Haematopoietic stem cell mobilisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-006367-26 Sponsor Protocol Number: IGTRegs Start Date*: 2023-01-03
    Sponsor Name:Πανεπιστήμιο Πατρών
    Full Title: Phase I / II study of HLA-G + induced T-regulatory cells (iG-Tregs) in patients after allogeneic hematopoietic stem cell transplantation from HLA compatible sibling / donor.
    Medical condition: Adopt immunotherapy in adult patients undergoing hematopoietic stem cell (HSCT) transplantation from a fully compatible donor sibling for the prevention and treatment of GvHD.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003626-88 Sponsor Protocol Number: HOO-MSC01 Start Date*: 2014-01-17
    Sponsor Name:Fakultní nemocnice Plzeň
    Full Title: The utilization of mesenchymal stem cells (MSC) for the treatment of graft versus host disease (GVHD) after allogeneic stem cell transplantation.
    Medical condition: The study is intended for patients after allogeneic hematopoietic stem cell transplantation (from related and unrelated donors) with steroid-refractory or steroid-dependent GVHD of any type: - Ste...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2006-004101-26 Sponsor Protocol Number: TJB0601P1 Start Date*: 2006-12-13
    Sponsor Name:CHU Sart-Tilman
    Full Title: Mesenchymal stem cell infusion as prevention for graft rejection and graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning: a pilot study
    Medical condition: Patients with hematological malignancies not candidate for conventional allogeneic transplantation because of age or comorbidities.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027703 Mismatched donor bone marrow transplantation therapy LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001335-31 Sponsor Protocol Number: virus-specific_CD8_T-cells_001 Start Date*: 2013-11-08
    Sponsor Name:Univerzita Karlova v Praze, 2. lékařská fakulta
    Full Title: Adoptive transfer of CMV specific CD8+ T-cells to treat CMV infection after transplantation
    Medical condition: chronic CMV infection after allogeneic hematopoietic stem cell transplantation in children, refractory to conventional antiviral treatment
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003185-26 Sponsor Protocol Number: CIK 2 Start Date*: 2009-04-14
    Sponsor Name:AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE)
    Full Title: Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK) cells after allogeneic stem cell transplantation
    Medical condition:  Patients with haematologic malignancies (excluding CML)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 Blood and lymphatic system disorders SOC
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003403-19 Sponsor Protocol Number: HCK1 Start Date*: 2013-09-25
    Sponsor Name:Karolinska University Hospital
    Full Title: Study of T- and B-cell immunity after vaccination with a virosomebased influenza vaccine (Inflexal V) in patients who have undergone hematopoietic allogeneic stem cell transplantation.
    Medical condition: Allogeneic stem cell transplantation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002434-40 Sponsor Protocol Number: AST-MOMA Start Date*: 2012-03-23
    Sponsor Name:University Hospital Tuebingen
    Full Title: Highdose Chemotherapy and transplantation of 34+ selected stem cell for progressive systemic sclerosis Modification according to manifestation
    Medical condition: Systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10059040 Autologous peripheral haematopoietic stem cell transplant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004545-18 Sponsor Protocol Number: NA Start Date*: 2005-04-26
    Sponsor Name:CHU Sart Tilman
    Full Title: Cell therapy for cardiac repair through mobilization of hematopoietic stem cells and endothelial progenitors in patients with chronic ischemic cardiomyopathy.
    Medical condition: Chronic ischemic cardiac disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000659-10 Sponsor Protocol Number: LMW-DS-103 Start Date*: 2014-05-21
    Sponsor Name:TikoMed AB
    Full Title: A randomised, open-label, placebo-controlled, single centre study in healthy male volunteers to explore efficacy, safety and tolerability of single doses of low molecular weight dextran sulfate (LM...
    Medical condition: Healthy volunteers (mobilization of haematopoietic stem cells)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10053948 Hematopoietic stem cell mobilization LLT
    Population Age: Adults Gender: Male
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003523-30 Sponsor Protocol Number: 38RC17.191 Start Date*: 2017-12-18
    Sponsor Name:University Hospital Grenoble
    Full Title: Vaccination after hematopoietic stem cell transplantation : a randomized study estimating the interest of an additional injection for patients not reponding at M3.
    Medical condition: Our aim is to determine whether an additional dose of inactivated vaccine can increase the rate of responders among patients who have not responded adequately after 3 injections
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10067859 Allogenic stem cell transplantation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005913-40 Sponsor Protocol Number: Treo TM Start Date*: 2006-01-17
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: A phase II, multicentre, clinical study evaluating the safety and efficacy of Treosulfan-based conditioning of allogenic transplantation of haemopoietic stem-cells in patients affected by Thalassem...
    Medical condition: Thalassemia Major
    Disease: Version SOC Term Classification Code Term Level
    6.1 10005329 SOC
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004122-41 Sponsor Protocol Number: 1 Start Date*: 2017-04-10
    Sponsor Name:Medical University Vienna, Dept. f. Transfusion Medicine
    Full Title: Plerixafor for stem cell mobilization in patients with multiple myeloma who mobilize moderate to optimize collection results - a randomized, placebo-controlled, double-blind study
    Medical condition: Stem cell mobilization with mozobil (plerixafor) in patients with multiple myeloma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000640-91 Sponsor Protocol Number: CMA-RC-03 Start Date*: 2005-06-10
    Sponsor Name:Institut de Recerca Hospital Sta. Creu i St. Pau
    Full Title: Treatment for acute myeloid leukemia (AML) during its first complete remision with the monoclonal antibody Mylotarg ® (anti-CD33/calicheamicina) pre- and post- autologous transplant of hematopoieti...
    Medical condition: Acute myeloid leukemia (AML) during its first complete remision and with high relapse risk, pre- and post- autologous hematopoiteic transplant
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023436-16 Sponsor Protocol Number: HOVON 107 Start Date*: 2011-05-31
    Sponsor Name:HOVON Foundation
    Full Title: The feasibility and efficacy of subcutaneous and intravenous Plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: a randomized phase II study.
    Medical condition: stem cell mobilization
    Disease: Version SOC Term Classification Code Term Level
    12.1 10053948 Hematopoietic stem cell mobilization LLT
    12.1 10024329 Leukemia LLT
    12.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Restarted)
    Trial results: View results
    EudraCT Number: 2012-002879-34 Sponsor Protocol Number: PSCT16 Start Date*: 2013-03-05
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Vaccination with minor histocompatibility antigen-loaded donor DC vaccines to boost graft-versus-tumor immunity after allogeneic stem cell transplantation
    Medical condition: Patients with aggressive hematological malignancies treated with allogeneic stem cell transplantation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002343-14 Sponsor Protocol Number: RAG1-2019-01 Start Date*: 2020-09-25
    Sponsor Name:Leiden University Medical Center
    Full Title: PHASE I/II CLINICAL TRIAL OF AUTOLOGOUS HEMATOPOIETIC STEM CELL GENE THERAPY FOR RAG1-DEFICIENT SEVERE COMBINED IMMUNODEFICIENCY
    Medical condition: Patients with severe combined immunodeficiency (SCID) based on a genetic defect in the Recombinase Activating Gene 1 (RAG1)
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 16:14:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA